Nuclear factor-κB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells

Clinical Cancer Research

Volumn 14, Issue 24, 2008, Pages 8143-8151

  Pan, Xue ^a,b   Arumugam, Thiruvengadam ^b   Yamamoto, Tameyoshi ^b   Levin, Pavel A ^b   Ramachandran, Vijaya ^b   Ji, Baoan ^b   Lopez Berestein, Gabriel ^b   Vivas Mejia, Pablo E ^b   Sood, Anil K ^b   McConkey, David J ^b   Logsdon, Craig D ^b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FLUORESCENCE ACTIVATED CELL SORTING; GEL MOBILITY SHIFT ASSAY; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR GROWTH; ANIMAL; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; GENE SILENCING; HUMANS; MALE; MICE; PANCREATIC NEOPLASMS; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR RELA;

EID: 58149359830     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1539     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer JClin 2006;56:106-30.
2. O'Reilly EM, Abou-Alfa GK. Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin Oncol 2007;34:347-53.
3. Moore MJ, Goldstein D, Hamm J,et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. JClin Oncol 2007;25:1960-6.
4. Nakanishi C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev 2005;5:297-309.
5. Neumann M, Naumann M. Beyond IκBS: alternative regulation of NF-κB activity. FASEB J 2007;21:2642-54.
6. Rayet B, Gelinas C. Aberrant Rel/NFκbgenes and activity in human cancer. Oncogene 1999;18:6938-47.
7. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5:119-27.
8. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM. Mitogenic and antiapoptotic role of constitutive NF-κB/Rel activity in pancreatic cancer. Int J Cancer 2003;105:735-46.
9. Chandler NM, Canete JJ, Callery MP. Increased expression of NF-κB subunits in human pancreatic cancer cells. J Surg Res 2004;118:9-14.
10. Arlt A, Gehrz A, Muerkoster S, et al. Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003;22:3243-51.
11. Arlt A, Schafer H. NFκB-dependent chemoresistance in solid tumors. Int JClin Pharmacol Ther 2002; 40:336-47.
12. Melisi D, Chiao PJ. NF-κ B as a target for cancer therapy. Exp Opin Ther Targets 2007;11:133-44.
13. Sebens S, Arlt A, Schafer H. NF-κBas a molecular target in the therapy of pancreatic carcinoma. Recent Res Cancer Res Fortschritte der Krebsforschung 2008;177:151 -64.
14. Arlt A, Vorndamm J, Breitenbroich M, et al. Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 2001;20:859-68.
15. Sato T, Odagiri H, Ikenaga SK, Maruyama M, Sasaki M. Chemosensitivity of human pancreatic carcinoma cells is enhanced by IκBα super-repressor. Cancer Sci 2003;94:467-72.
16. Kuhnel F, Zender L, Paul Y, et al. NFκB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. J Biol Chem 2000;275:6421 -7.
17. Reuther-Madrid JY, Kashatus D, Chen S, et al. The p65/RelA subunit of NF-κB suppresses the sustained, antiapoptotic activity of Jun kinase induced by tumor necrosis factor. Mol Cell Biol 2002;22:8175-83.
18. Ortis F, Cardozo AK, Crispim D, S torling J, Mandrup-Poulsen T, Eizirik DL. Cytokine-induced proapoptotic gene expression in insulin-producing cells is related to rapid, sustained, and nonoscillatory nuclear factor-κB activation. Mol Endocrinol (Baltimore MD) 2006;20: 1867-79.
19. Bian X, McAllister-Lucas LM, Shao F, et al. NF-κB activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J Biol Chem 2001;276:48921 -9.
20. Dong QG, Sclabas GM, Fujioka S, et al. The function of multiple IκB: NF-κB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 2002;21:6510-9.
21. Ouyang H, Mou L, Luk C, et al. Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am JPathol 2000;157:1623-31.
22. Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 2003;100:183-8.
23. Landen CN, Merritt WM, Mangala LS, et al. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther 2006;5:1708-13.
24. Weichert W, Boehm M, GekelerV, et al. High expression of RelA/p65 is associated with activation of nuclear factor-κB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer 2007;97:523-30.
25. Banerjee S, Zhang Y, Ali S, et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 2005;65:9064-72.
26. Muerkoster S, Arlt A, Witt M, et al. Usage of the NF-κB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer 2003;104:469-76.
27. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-κB-regulated gene products. Cancer Res 2007; 67:3853-61.
28. Bai J, Demirjian A, Sui J, Marasco W, Callery MP. Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun 2006;348:1245-53.
29. Li Y, EllisKL, AliS,et al. Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-κBin BxPC-3 pancreatic cancer cell line. Pancreas 2004;28:e90-5.
30. Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R. Nuclear factor-κBand In Bkinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 2004;101:2351 -62.
31. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH. Inactivation of nuclear factor κB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 2005;65:6934-42.
32. Chen LF, Greene WC. Shaping the nuclear action of NF-κB. Nat Rev Mol Cell Biol 2004;5:392-401.
33. Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 2002;5:19-33.
34. Giroux V, Malicet C, Barthet M, et al. p8 is a new target of gemcitabine in pancreatic cancer cells. Clin Cancer Res 2006;12:235-41.
35. Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, et al. Proteomics finding heat shock protein 27 as a bio-marker for resistance of pancreatic cancer cells to gemcitabine. Int JOncol 2007;31:1345-50.
36. Mahon PC, Baril P, Bhakta V, et al. S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res 2007;67:6786-95.
37. Okamoto K, Ocker M, Neureiter D, et al. Bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells. J Cell Mol Med 2007;11:349-61.
38. Bold RJ, Chandra J, McConkey DJ. Gemcitabineinduced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol 1999;6:279-85.
39. Shah AN,Summy JM, Zhang J,ParkSI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007;14:3629-37.